Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
87 articles
(Page 2)
Neoadjuvant Endocrine Therapy Reduces Mastectomy Rates in Early Breast Cancer
Meta-analysis shows neoadjuvant endocrine therapy lowers mastectomy rates in ER-positive early breast cancer.
Genetic Variants Linked to Higher Mortality Risk in Cancer Chemotherapy
Meta-analysis reveals DPYD gene variants significantly increase death risk in fluoropyrimidine chemotherapy.
Cabazitaxel: A Promising Second-Line Treatment for Advanced Prostate Cancer
Meta-analysis shows cabazitaxel improves survival in metastatic castration-resistant prostate cancer patients.
Breakthrough Combo Therapy Outperforms Standard Treatment in Advanced Lung Cancer
New drug combination shows promising results in treating advanced EGFR-mutated lung cancer patients.
Acupressure: A Promising Complementary Therapy for Chemotherapy-Induced Nausea in Breast Cancer
Study shows acupressure reduces chemotherapy-induced nausea and vomiting in breast cancer patients.
Pembrolizumab Shows Promise in Advanced Merkel Cell Carcinoma: KEYNOTE-913 Results
Phase III trial demonstrates efficacy and safety of pembrolizumab for advanced Merkel cell carcinoma.
Capmatinib Shines in METex14 NSCLC: GEOMETRY mono-1 Trial Unveils Promising Results
Final results from GEOMETRY mono-1 trial show capmatinib's efficacy in METex14 NSCLC, especially first-line.
Immunotherapy Breakthrough: Pembrolizumab Boosts Survival in Early-Stage Lung Cancer
Pembrolizumab plus chemotherapy improves survival in resectable early-stage non-small cell lung cancer.
Immunotherapy Breakthrough: Pembrolizumab Boosts Survival in Advanced Cervical Cancer
Pembrolizumab plus chemoradiotherapy significantly improves survival in high-risk cervical cancer patients.
7-Year Follow-Up: Pembrolizumab Shines in High-Risk Melanoma
Long-term study shows sustained benefits of adjuvant pembrolizumab in resected stage III melanoma.
New Analysis Supports Flexible Dosing Options for CML Drug Asciminib
Study shows similar efficacy and safety for once-daily and twice-daily asciminib dosing in CML patients.
Promising Brain Breakthrough: T-DXd Shows Hope for HER2-Low Breast Cancer with Brain Metastases
T-DXd demonstrates encouraging intracranial activity in HER2-low breast cancer patients with brain metastases.